Alimera Sciences, Inc. (ALIM) Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. decreased its stake in Alimera Sciences, Inc. (NASDAQ:ALIM) by 40.3% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 303,823 shares of the biopharmaceutical company’s stock after selling 205,280 shares during the period. Goldman Sachs Group Inc. owned approximately 0.46% of Alimera Sciences worth $422,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. JW Asset Management LLC grew its stake in shares of Alimera Sciences by 15.6% in the second quarter. JW Asset Management LLC now owns 966,000 shares of the biopharmaceutical company’s stock worth $1,343,000 after acquiring an additional 130,000 shares during the last quarter. KCG Holdings Inc. grew its stake in shares of Alimera Sciences by 127.0% in the first quarter. KCG Holdings Inc. now owns 78,604 shares of the biopharmaceutical company’s stock worth $110,000 after acquiring an additional 43,977 shares during the last quarter. Finally, PNC Financial Services Group Inc. grew its stake in shares of Alimera Sciences by 24.3% in the second quarter. PNC Financial Services Group Inc. now owns 180,300 shares of the biopharmaceutical company’s stock worth $251,000 after acquiring an additional 35,200 shares during the last quarter. Institutional investors and hedge funds own 36.82% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was first posted by Stock Observer and is the property of of Stock Observer. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at https://www.thestockobserver.com/2017/11/15/alimera-sciences-inc-alim-shares-sold-by-goldman-sachs-group-inc.html.

ALIM has been the topic of several research analyst reports. HC Wainwright set a $5.00 price objective on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Cowen and Company set a $3.00 price objective on shares of Alimera Sciences and gave the stock a “buy” rating in a research note on Tuesday, July 25th. ValuEngine downgraded shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Finally, Zacks Investment Research downgraded shares of Alimera Sciences from a “hold” rating to a “sell” rating in a research note on Thursday, August 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $3.38.

Alimera Sciences, Inc. (NASDAQ:ALIM) opened at $1.21 on Wednesday. Alimera Sciences, Inc. has a 12-month low of $1.04 and a 12-month high of $1.72. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Want to see what other hedge funds are holding ALIM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alimera Sciences, Inc. (NASDAQ:ALIM).

Institutional Ownership by Quarter for Alimera Sciences (NASDAQ:ALIM)

Receive News & Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply